Please assess the completion status of the following clinical trial:

Trial Title: Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (Patients):~1. Male or females between the ages of 18-35~2. less than five years (\<60 months) of active Diagnostic and Statistical Manual of Mental Disorders (DSM) diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder~3. Capacity to provide informed consent~4. No major medical or neurological illness~5. Medication free (3 weeks without antipsychotic medications)~Exclusion Criteria (Patients):~1. Current alcohol or drug abuse (\<1 month) or substance dependence (\<6 months) or substances used within one day of the imaging study.~2. Pregnant or lactating women or women of child-bearing potential, who are either not surgically-sterile or, for outpatients, not using appropriate methods of birth control.~3. Intelligence Quotient (IQ) \<70~4. Acute risk for suicide or violence~5. Presence of pacemaker or any metallic objects in the body that would interfere with the MRS or cause MRI safety problems~6. Claustrophobia~7. Any organic brain disorder (including epilepsy, mental retardation, or a medical condition whose pathology or treatment would likely alter the presentation or treatment of SZ~8. Individuals on anti-epileptic medications (e.g., valproate, carbamazepine) that may affect GABA or Glu~9. Unstable medical or neurological condition~10. DSM-V diagnosis of bipolar disorder I~11. DSM-V diagnosis of major depression with psychotic features~12. History of non-response to or non-tolerance of Risperidone~Inclusion Criteria (Healthy Controls)~1. Male or females between the ages of 18-35~2. less than five years (\<60 months) of active DSM diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder~3. No major medical or neurological illness~Exclusion Criteria (Healthy Controls)~1. Current alcohol or drug abuse (\<1 month) or substance dependence (\<6 months) or substances used within one day of the imaging study.~2. Pregnant or lactating women or women of child-bearing potential, who are either not surgically-sterile or, for outpatients, not using appropriate methods of birth control.~3. IQ\<70~4. Acute risk for suicide or violence~5. Presence of pacemaker or any metallic objects in the body that would interfere with the MRS or cause MRI safety problems~6. Claustrophobia~7. History of psychotropic medication use such as antipsychotics or antidepressants~8. Any first-degree family history of psychotic illness~9. Personal history of any DSM Axis I disorder~10. Individuals on anti-epileptic medications (e.g., valproate, carbamazepine) that may affect GABA or Glu~11. Unstable medical or neurological condition~12. Any organic brain disorder (including epilepsy, mental retardation, or a medical condition whose pathology or treatment would likely alter the presentation or treatment of SZ

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Patient (Type: EXPERIMENTAL): Medication-free individuals during first-episode of psychosis who will receive 4 weeks of treatment with risperidone
- Control (Type: NO_INTERVENTION): Healthy, psychosis-free controls who will not receive risperidone

Based on this trial design, predict the completion outcome and termination type (if applicable).